Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials
82 studies found for:    si-bone
Show Display Options
Rank Status Study
1 Recruiting LOIS: Long-Term Follow-Up in INSITE/SIFI
Conditions: Degenerative Sacroilitis;   Sacroiliac Joint Disruption
Intervention: Radiation: Pelvic CT at 5 years post-op
2 Recruiting Validity and Reliability of Diagnostic Findings of SI Joint Blocking
Condition: SI Joint Pain
Interventions: Drug: 0.75% bupivacaine;   Drug: .75% bupivacaine
3 Active, not recruiting Investigation of Sacroiliac Fusion Treatment (INSITE)
Conditions: Degenerative Sacroiliitis;   Sacroiliac Joint Disruption
Interventions: Device: iFuse Implant System;   Other: Non-surgical management
4 Active, not recruiting Sacroiliac Joint Fusion With iFuse Implant System (SIFI)
Conditions: Degenerative Sacroiliitis;   Sacroiliac Joint Disruption
Intervention:
5 Recruiting iFuse Implant System® Minimally Invasive Arthrodesis
Condition: Chronic, Disabling Sacroiliac Joint Pain
Interventions: Device: iFuse Implant System;   Other: Conservative Management
6 Recruiting REVIVE(Randomized Exploratory Clinical Trial to Evaluate the Safety and Effectiveness of Stem Cell Product in Alcoholic Liver Cirrhosis Patient)
Condition: Alcoholic Liver Cirrhosis
Intervention: Biological: Livercellgram
7 Recruiting Outcome Comparison of Allograft and Synthetic Bone Substitute in High Tibial Osteotomy
Condition: Osteoarthritis, Knee
Interventions: Procedure: Allogenic bone graft;   Procedure: Synthetic bone substitute (geneX®)
8 Completed
Has Results
3 yr Efficacy & Safety Study of Zoledronic Acid in Post-menopausal Women With Osteoporosis Treated With Zol Acid for 6 Yrs
Condition: Post-menopausal Osteoporosis
Interventions: Drug: Placebo;   Drug: Zoledronic acid
9 Completed Comparison of Bone Mineral Loss in Prostate Cancer Patients Who is Receiving GnRH Agonist and -Plus Anti-androgen Agent
Condition: GnRH Agonist Alone vs. GnRH Agonist Plus Anti-androgen Combination Treated Prostate Cancer Patients
Intervention:
10 Recruiting Evaluation of Safety and Efficacy of Nasea(R)/Ramosetron Inj. in Patients Undergoing Facial Bone Fracture Operations
Condition: Facial Bones Fracture
Intervention: Drug: Ramosetron
11 Active, not recruiting A Longitudinal 2-year Bone Marrow Study of Eltrombopag in Previously Treated Adults, With Chronic Immune (Idiopathic) Thrombocytopenic Purpura (ITP)
Condition: Purpura, Thrombocytopenic, Idiopathic
Intervention: Drug: Eltrombopag olamine
12 Completed
Has Results
A Phase III Trial of ZD4054 (Zibotentan) (Endothelin A Antagonist) in Hormone Resistant Prostate Cancer With Bone Metastases
Condition: Prostate Cancer
Interventions: Drug: ZD4054;   Drug: Placebo
13 Recruiting Trial of Docetaxel and Irinotecan (DI) for Recurrent or Refractory Bone and Soft Tissue Sarcomas.
Condition: Sarcoma
Interventions: Drug: Docetaxel (Taxotere);   Drug: Irinotecan
14 Completed
Has Results
Efficacy in Reducing Fractures and Safety of Zoledronic Acid in Men With Osteoporosis
Condition: Male Osteoporosis
Interventions: Drug: Zoledronic acid 5 mg iv;   Drug: Placebo
15 Completed
Has Results
Evaluation of Fusion Rate of Anterior Cervical Discectomy and Fusion (ACDF) Using Cervios ChronOs™ and Bonion™
Conditions: Intervertebral Disk Degeneration;   Intervertebral Disk Displacement;   Ossification of Posterior Longitudinal Ligament
Interventions: Device: Cervios ChronOs;   Device: Bonion
16 Unknown  Effect of Local Pamidronate in Preventing Bone Loss After Total Hip Arthroplasty
Conditions: Arthroplasty;   Mineral Density
Intervention: Drug: pamidronate
17 Recruiting Study to Show Treatment With D'Mab as Good as Treatment With Risedronate in Subjects Start to Take or Taking GCs
Condition: Steroid-induced Osteporosis, Glucocorticoid-induced Osteporosis
Interventions: Drug: Active denosumab with placebo for risedronate;   Drug: Active risedronate with placebo for denosumab
18 Active, not recruiting Study of Denosumab as Adjuvant Treatment for Women With High Risk Early Breast Cancer Receiving Neoadjuvant or Adjuvant Therapy (D-CARE)
Condition: Breast Cancer
Interventions: Drug: Placebo;   Drug: Denosumab
19 Not yet recruiting Study of Radium-223 Dichloride Versus Placebo and Treatment With Exemestane / Everolimus in Subjects With Bone Predominant HER2 (Human Epidermal Growth Factor Receptor 2) Negative Hormone Receptor Positive Metastatic Breast Cancer
Condition: Breast Neoplasms
Interventions: Drug: Radium-223 dichloride (Xofigo, BAY88-8223);   Drug: Placebo (saline);   Drug: Exemestane;   Drug: Everolimus
20 Active, not recruiting Randomized Study of ON 01910.Na in Refractory Myelodysplastic Syndrome Patients With Excess Blasts
Conditions: Myelodysplastic Syndromes;   MDS;   RAEB;   Chronic Myelomonocytic Leukemia
Intervention: Drug: ON 01910.Na

   Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results    Last Page
Indicates status has not been verified in more than two years